Acotec Scientific Holdings Limited (6669) AI Stock Analysis

• Market Cap: HK$4.14B
• Dividend Yield: N/A
• Average Volume (3M): 462.19K
• Price to Earnings (P/E): 36.6
• Beta (1Y): 1.05
• Revenue Growth: 12.94%
• EPS Growth: 212.66%
• Country: HK
• Employees: 650
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.32
• Shares Outstanding: 313,389,160
• 10 Day Avg. Volume: 400,669
• 30 Day Avg. Volume: 462,190
• PEG Ratio: 0.13
• Price to Book (P/B): 1.25
• Price to Sales (P/S): 3.16
• P/FCF Ratio: 317.86
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$15.00
• Price Target Upside: 5.93% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 2.8
• Revenue Forecast (FY): HK$5.54B

• Rating: 67 Neutral
• Price Target: HK$13.50 ▼(-4.66% Downside)

Acotec Scientific Holdings Limited shows strong financial performance with robust revenue growth and cash flow metrics, which are the most significant factors supporting its stock score. However, the technical indicators suggest neutral market sentiment, and the high P/E ratio indicates potential overvaluation, which slightly dampens the overall score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective sales strategies, supporting long-term business expansion and stability.

Cash Flow Improvement

Improved cash flow enhances financial flexibility, allowing for reinvestment in growth opportunities and strengthening the company's financial position.

Strong Gross Profit Margin

A strong gross profit margin reflects efficient cost control and pricing power, which supports sustainable profitability and competitive advantage.

Negative Factors

Moderate Profitability

Moderate net profitability indicates potential challenges in converting revenue to profit, which may impact long-term financial performance if not addressed.

Leverage Concerns

Moderate ROE suggests limited efficiency in using equity to generate profits, which could constrain growth and shareholder returns over time.

Potential for Enhanced Profitability

While financial health is strong, the potential for improved profitability highlights the need for strategic initiatives to boost bottom-line growth.

Acotec Scientific Holdings Limited Business Overview & Revenue Model

Company Description

Acotec Scientific Holdings Limited, a medical device company, researches and develops percutaneous transluminal angioplasty and drug-coated balloon products for the treatment of vascular diseases in Mailand China, Europe, and internationally. It offers AcoArt Orchid & Dhalia to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease; under clinical studies in nephrology for arteriovenous fistula stenosis and in neurology for vertebral atherosclerotic stenosis indications/applications; and under clinical studies in andrology for vasculogenic erectile dysfunction indications/applications. The company also provides AcoArt Tulip & Litos, which is under registration process in China and Europe, and under preclinical studies in the United States in vascular surgery for below-the-knee artery disease indications/applications; and in pre-clinical studies in andrology for vasculogenic erectile dysfunction indications/applications. The company was incorporated in 2020 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited is a subsidiary of CA Medtech Investment (Cayman) Limited.

How the Company Makes Money

Acotec Scientific Holdings Limited generates revenue primarily through the sale of its medical devices, which are marketed to hospitals and healthcare providers. The company employs a business-to-business (B2B) revenue model, where it sells its products directly to medical institutions and distributors. Key revenue streams include sales from its proprietary catheter systems and related accessories. Additionally, Acotec may engage in strategic partnerships with healthcare organizations and research institutions to expand its product offerings or enhance its market reach, which can also contribute to revenue growth. The company's focus on innovation and product development, along with its ability to address unmet medical needs, plays a critical role in driving its earnings.

Acotec Scientific Holdings Limited Financial Statement Overview

Summary

Acotec Scientific Holdings Limited exhibits strong financial health with consistent revenue growth, robust gross profit margins, and improving cash flow metrics. The balance sheet remains solid with low leverage, although there is potential for enhancing net profitability.

Income Statement

Acotec Scientific Holdings Limited has demonstrated consistent revenue growth with a 5.22% increase in the TTM period. The company maintains a strong gross profit margin of 75.23%, indicating effective cost management. However, the net profit margin of 17.02% suggests room for improvement in profitability. The EBIT margin of 10.11% and EBITDA margin of 13.68% are healthy, reflecting operational efficiency.

Balance Sheet

The company's balance sheet is stable with a low debt-to-equity ratio of 0.16, indicating conservative leverage. The return on equity (ROE) of 7.22% shows moderate profitability relative to shareholder equity. The equity ratio of 79.01% suggests a strong equity position, providing a solid financial foundation.

Cash Flow

Acotec Scientific Holdings Limited has shown significant improvement in cash flow, with a 51.62% growth in free cash flow. The operating cash flow to net income ratio of 0.90 indicates strong cash generation relative to net income. The free cash flow to net income ratio of 0.82 further supports the company's ability to generate cash, enhancing financial flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	592.85M	533.99M	473.85M	395.55M	303.81M	193.97M
Gross Profit	446.01M	402.72M	377.42M	336.35M	265.94M	163.78M
EBITDA	81.08M	112.48M	70.54M	91.17M	-51.02M	-24.66M
Net Income	100.90M	52.28M	14.49M	70.14M	-79.08M	-43.84M
Balance Sheet
Total Assets	1.83B	1.66B	1.61B	1.41B	1.31B	272.94M
Cash, Cash Equivalents and Short-Term Investments	995.38M	809.57M	879.21M	986.46M	1.14B	147.10M
Total Debt	236.13M	202.92M	234.00M	47.78M	24.57M	41.41M
Total Liabilities	384.00M	312.76M	314.53M	134.46M	100.17M	553.95M
Stockholders Equity	1.44B	1.35B	1.30B	1.28B	1.21B	-281.01M
Cash Flow
Free Cash Flow	159.00M	5.31M	-92.54M	-115.45M	-31.72M	-27.39M
Operating Cash Flow	194.51M	102.79M	-12.88M	-68.75M	-10.48M	-8.77M
Investing Cash Flow	-203.20M	45.02M	-319.22M	-49.17M	-20.48M	-17.73M
Financing Cash Flow	-35.32M	-35.24M	-23.21M	-32.87M	1.02B	142.52M

Acotec Scientific Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 14.16
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6669, the sentiment is Neutral. The current price of 14.16 is above the 20-day moving average (MA) of 13.55, above the 50-day MA of 12.88, and above the 200-day MA of 10.95, indicating a neutral trend. The MACD of 0.26 indicates Positive momentum. The RSI at 47.72 is Neutral, neither overbought nor oversold. The STOCH value of 37.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:6669.

Acotec Scientific Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6669	67 Neutral	HK$4.14B	36.62	7.44%	―	12.94%	212.66%
6609	60 Neutral	HK$2.37B	50.88	3.84%	―	32.93%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2160	46 Neutral	HK$7.64B	545.45	0.22%	―	-4.38%	―
2235	44 Neutral	HK$3.15B	-103.74	-1.39%	―	49.86%	80.35%
2500	41 Neutral	HK$1.12B	-1.59	-26.80%	―	-8.56%	-14.84%
9996	39 Underperform	HK$4.43B	-18.06	-11.20%	―	29.25%	9.02%

Acotec Scientific Holdings Limited Corporate Events

Acotec Shareholders Approve 2026 Collaboration Framework With Controlling Shareholder BSG

Acotec Scientific Holdings Limited announced that all resolutions proposed at its extraordinary general meeting held in Beijing on 31 December 2025 were duly passed by shareholders through poll voting. Independent shareholders representing about 61.2% of the eligible free-float participated, with the key ordinary resolution approving, ratifying and confirming the 2026 Master Collaboration Agreement with controlling shareholder BSG, including the framework for non-exempt continuing connected transactions and related annual caps. The strong approval level, with over 99% of votes cast in favour of the main resolution and the controlling shareholder abstaining as required, provides formal shareholder backing for the company’s planned collaboration framework with BSG, paving the way for continued operational cooperation under clearer governance and compliance with Hong Kong listing rules.

The most recent analyst rating on (HK:6669) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Acotec Scientific Holdings Limited stock, see the HK:6669 Stock Forecast page.

Acotec Scientific to Hold EGM for Key Agreement Approvals

Acotec Scientific Holdings Limited has announced an extraordinary general meeting scheduled for December 31, 2025, to approve and ratify two significant agreements with BSG. These agreements, the 2026 Master Collaboration Agreement and the 2026 Master Service Agreement, are expected to impact the company’s operations by establishing new collaborative and service frameworks, potentially enhancing its industry positioning and stakeholder relations.

The most recent analyst rating on (HK:6669) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Acotec Scientific Holdings Limited stock, see the HK:6669 Stock Forecast page.

Acotec Extends Strategic Collaboration with Boston Scientific Group

Acotec Scientific Holdings Limited has entered into two significant agreements with its controlling shareholder, Boston Scientific Group Limited (BSG), to extend their collaboration and service arrangements for another three years, from January 1, 2026, to December 31, 2028. These agreements, known as the 2026 Master Collaboration Agreement and the 2026 Master Service Agreement, aim to enhance the cross-selling, distribution, and manufacturing services of Acotec’s products, including new and improved offerings, across various regions. The agreements are classified as continuing connected transactions under the Hong Kong Stock Exchange Listing Rules, requiring independent shareholders’ approval due to the significant percentage ratios involved. This strategic move is expected to strengthen Acotec’s market position and expand its product reach, benefiting stakeholders through improved business synergies and operational efficiencies.

The most recent analyst rating on (HK:6669) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Acotec Scientific Holdings Limited stock, see the HK:6669 Stock Forecast page.

Acotec Scientific Announces EGM and Closure of Register of Members

Acotec Scientific Holdings Limited has announced the closure of its register of members in preparation for an extraordinary general meeting (EGM) scheduled for December 31, 2025. This closure, from December 24 to December 31, 2025, is to determine shareholder eligibility to attend and vote at the EGM. Shareholders must ensure their shares are registered by December 23, 2025, to participate. The company plans to dispatch a circular with details of the resolutions to be proposed at the EGM by December 17, 2025.

The most recent analyst rating on (HK:6669) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Acotec Scientific Holdings Limited stock, see the HK:6669 Stock Forecast page.

Acotec Scientific Secures Approval for Microcatheter V-otter

Acotec Scientific Holdings Limited announced that it has received registration approval from the PRC National Medical Products Administration for its new product, the Microcatheter V-otter. This microcatheter is designed for Transarterial Chemoembolization (TACE) procedures and features a large-lumen design to prevent catheter occlusion, offering various tip configurations for precise access to target vessels. The company plans to market this product in the PRC market, although there is no guarantee of successful commercialization.

The most recent analyst rating on (HK:6669) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Acotec Scientific Holdings Limited stock, see the HK:6669 Stock Forecast page.

Acotec Scientific Gains Approval for New Cardiovascular Device

Acotec Scientific Holdings Limited announced that it has received approval from the PRC National Medical Products Administration for its Coronary Over-the-Wire Balloon Dilatation Catheter Jingyi. This product is designed to improve myocardial perfusion by addressing complex coronary artery lesions, and the company plans to market it in the PRC. The approval marks a significant step in Acotec’s product development, potentially enhancing its market position in the cardiovascular medical device sector.

The most recent analyst rating on (HK:6669) stock is a Hold with a HK$14.50 price target. To see the full list of analyst forecasts on Acotec Scientific Holdings Limited stock, see the HK:6669 Stock Forecast page.

Acotec’s Endovenous System Gains U.S. FDA Clearance

Acotec Scientific Holdings Limited announced that its Endovenous Radiofrequency Ablation System has received 510(k) clearance from the U.S. FDA, marking a significant milestone in its product development. This clearance allows the company to distribute the system, which treats varicose veins, in the U.S. through a partnership with the BSC Group, potentially enhancing its market presence and offering new opportunities for growth.

The most recent analyst rating on (HK:6669) stock is a Hold with a HK$14.00 price target. To see the full list of analyst forecasts on Acotec Scientific Holdings Limited stock, see the HK:6669 Stock Forecast page.